TrialRMD open2026

Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis.

Walter P Maksymowych et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.